The results of this pooled analysis highlight the idea that the exon 19del mutation is a better indicator of strong efficacy in EGFR TKI treatment, which is an improvement over findings in patients with lung cancer that have been reported previously. This evidence concerns the gene EGFR and lung carcinoma.